Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of empagliflozin on proteinuria in glomerulonephritis
IRCT20090127001598N6Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of empagliflozin in Glomerulonephritis (GN) and proteinuria, sponsored by Isfahan University of Medical Sciences. Primary endpoint: Change in proteinuria. Started Nov 2021; status: completed.
02
Drugs
empagliflozin
03
Conditions
Glomerulonephritis (GN)proteinuria
Beyond the preview
Go deeper on IRCT20090127001598N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090127001598N6.